

## Technology Appraisal Committee A Interests Register

**Topic: Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]**

**Publication Date: 17<sup>th</sup> December 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Matthew Walton	TAC Committee Member	Non-Financial Professional interests	Matthew was the lead EAG economist for the original company submission of palopegteriparatide. The topic was paused in response to concerns we raised with the evidence submission, which was revised and the model rebuilt (notionally) on the basis of detailed feedback we provided to the company. Whilst he was not involved in the preparation of the EAG Report considered in the October ACM, he feels his involvement in the earlier stages of the process means it is inappropriate to participate in this discussion.	12/09/2025	It was agreed that Matthew Walton's declaration would prevent him from participating in discussions on this appraisal.
Otilia Buch	Clinical Expert	Direct Financial	<ul style="list-style-type: none"> <li>▪ Attended pharma organised study days (fully sponsored) –</li> <li>▪ 15-16 May 2024 IPSEN (Acromegaly)</li> <li>▪ 20 June 2024 Amegen (Osteoporosis)</li> <li>▪ 8 July 2024 Pfizer (Acromegaly)</li> </ul>	07/10/2025	It was agreed that Otilia Buch's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Direct non-financial	<ul style="list-style-type: none"> <li>Currently part of the European Society of Endocrinology clinical guideline working group to develop the updated CG for the management of Chronic Hypoparathyroidism</li> </ul>		